21 May 2024
Scancell Holdings plc
("Scancell" or the "Company")
Issue of share
options
Scancell Holdings plc (AIM: SCLP), the
developer of novel immunotherapies for the treatment of cancer,
announces that on 20 May 2024 it has granted share options to
acquire ordinary shares of 0.1 pence each in the capital of the
Company to Sath Nirmalananthan, CFO and Executive
Director.
These share options have an exercise price of
10.1pence each, the closing share price on 20 May 2024, and will
vest over three years in three equal tranches from 29 August 2024
with no vesting criteria other than to remain in employment. Any
unexercised share options which are being granted per the above
will expire at 6pm on 19 May 2034.
The Board of Scancell approved the issuance of
share option grants to incentivise and retain directors and staff
of the Company. The Board considered both historical practices and
on-going funding requirements in this regard.
Related Party Transaction
The issue of share options to Sath
Nirmalananthan are deemed to be a related party transaction
pursuant to AIM Rule 13 of the AIM Rules for Companies. The
Company's directors who are independent of the related party
transaction, being all the directors other than Sath
Nirmalananthan, consider, having consulted with the Company's
Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms
of the related party transactions are fair and reasonable insofar
as the shareholders of the Company are concerned.
NOTIFICATION AND PUBLIC DISCLOSURE OF
TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Sath Nirmalananthan
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer and PDMR
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
|
|
a)
|
Name
|
Scancell Holdings plc
|
|
b)
|
LEI
|
2138008RXEG856SNP666
|
|
4
|
Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
|
Options to acquire ordinary shares
|
|
b)
|
Identification Code
|
GB00B63D3314
|
|
c)
|
Nature of the transaction
|
Grant of options to acquire ordinary
shares
|
|
|
|
|
|
d)
|
Price(s) and volume(s)
|
1,000,000 share options
10.1 pence per share
option
|
|
e)
|
Aggregated information
- Aggregated volume
- Price
|
N/A (single transaction)
|
|
f)
|
Date of the transaction
|
20 May 2024
|
|
g)
|
Place of the transaction
|
Outside a trading venue
|
|
For further information, please
contact:
|
|
|
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
|
|
|
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare
Investment Banking)
Nick Harland (Corporate Broking)
|
|
|
|
|
|
WG Partners LLP
(Joint Broker)
|
+44(0) 20 3705 9330
|
|
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
|
|
|
|
|
Panmure Gordon
(UK) Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
|
|
|
|
|
Consilium
Strategic Communications
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela Gray/Lindsey
Neville
|
scancell@consilium-comms.com
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and
ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and
ImmunoBody®) this includes
citrullination and homocitrullination of proteins, whereas its mAb
portfolio targets glycans or sugars that are added onto proteins
and / or lipids (GlyMab®) or enhances the potency of
antibodies and their ability to directly kill tumour cells
(AvidiMab®).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
